MA39154A1 - Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol - Google Patents

Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol

Info

Publication number
MA39154A1
MA39154A1 MA39154A MA39154A MA39154A1 MA 39154 A1 MA39154 A1 MA 39154A1 MA 39154 A MA39154 A MA 39154A MA 39154 A MA39154 A MA 39154A MA 39154 A1 MA39154 A1 MA 39154A1
Authority
MA
Morocco
Prior art keywords
formoterol
combination
glycopyrronium bromide
aerosol solution
hydroxy
Prior art date
Application number
MA39154A
Other languages
English (en)
Inventor
Sauro Bonelli
Diego Copelli
Alberi Massimiliano Dagli
Francesca Usberti
Enrico Zambelli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49886776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA39154A1 publication Critical patent/MA39154A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/007—Mechanical counters
    • A61M15/0071—Mechanical counters having a display or indicator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
    • B65D83/44—Valves specially adapted therefor; Regulating devices
    • B65D83/52—Valves specially adapted therefor; Regulating devices for metering
    • B65D83/54—Metering valves ; Metering valve assemblies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
    • B65D83/75—Aerosol containers not provided for in groups B65D83/16 - B65D83/74
    • B65D83/752—Aerosol containers not provided for in groups B65D83/16 - B65D83/74 characterised by the use of specific products or propellants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A61M2039/226—Spindles or actuating means

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition de solution pour aérosol destinée à être utilisée avec un inhalateur-doseur pressurisé, comprenant du bromure de glycopyrronium et du formotérol, ou un sel correspondant, éventuellement en combinaison avec un ou plusieurs principes actifs supplémentaires, stabilisée par une quantité choisie d'un acide minéral et la quantité du produit de dégradation n-(3-bromo)-[2-hydroxy-5-[1-hydroxy-2-[1-(4-méthoxyphényl)propan-2-ylamino]éthyl]phényl]formamide étant inférieure à la limite de quantification lorsqu'elle est stockée dans des conditions accélérées à 25°c et à 60 % d'humidité relative (hr) pendant au moins 3 mois dans une bombe à aérosol équipée d'une soupape de dosage présentant au moins un joint en caoutchouc de butyle. Ledit un ou lesdits plusieurs principes actifs supplémentaires peuvent être un corticostéroïde d'inhalation choisi parmi le dipropionate de béclométasone, le budésonide ou son épimère 22r, le ciclésonide, le flunisolide, le propionate de fluticasone, le furoate de fluticasone, le furoate de mométasone, etc.
MA39154A 2013-12-30 2014-12-23 Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol MA39154A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199783 2013-12-30
PCT/EP2014/079258 WO2015101575A1 (fr) 2013-12-30 2014-12-23 Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol

Publications (1)

Publication Number Publication Date
MA39154A1 true MA39154A1 (fr) 2017-08-31

Family

ID=49886776

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39154A MA39154A1 (fr) 2013-12-30 2014-12-23 Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol

Country Status (36)

Country Link
US (3) US20150182459A1 (fr)
EP (1) EP3096737B1 (fr)
JP (2) JP6534397B2 (fr)
KR (1) KR101865131B1 (fr)
CN (2) CN113143894A (fr)
AR (1) AR098983A1 (fr)
AU (1) AU2014375300B2 (fr)
BR (1) BR112016014586A2 (fr)
CA (1) CA2935302C (fr)
CL (1) CL2016001652A1 (fr)
CY (1) CY1120205T1 (fr)
DK (1) DK3096737T3 (fr)
EA (1) EA033228B1 (fr)
ES (1) ES2666905T4 (fr)
GE (1) GEP20186870B (fr)
HR (1) HRP20180944T1 (fr)
HU (1) HUE039359T2 (fr)
IL (1) IL246502B (fr)
LT (1) LT3096737T (fr)
MA (1) MA39154A1 (fr)
ME (1) ME03076B (fr)
MX (1) MX368834B (fr)
MY (1) MY176191A (fr)
NO (1) NO3096737T3 (fr)
PE (1) PE20161132A1 (fr)
PH (1) PH12016501269A1 (fr)
PL (1) PL3096737T3 (fr)
PT (1) PT3096737T (fr)
RS (1) RS57269B1 (fr)
SA (1) SA516371428B1 (fr)
SG (1) SG11201605309UA (fr)
SI (1) SI3096737T1 (fr)
TN (1) TN2016000262A1 (fr)
TR (1) TR201809356T4 (fr)
UA (1) UA117846C2 (fr)
WO (1) WO2015101575A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160853A1 (es) 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
WO2015101575A1 (fr) * 2013-12-30 2015-07-09 Chiesi Farmaceutici S.P.A. Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol
PL3089735T3 (pl) * 2013-12-30 2018-12-31 Chiesi Farmaceutici S.P.A. Trwała ciśnieniowa kompozycja roztworu aerozolowego kombinacji bromku glikopironium i formoterolu
GB201520862D0 (en) * 2015-11-25 2016-01-13 Jagotec Ag Pharmaceutical composition
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
ES2968453T3 (es) 2016-09-19 2024-05-09 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
EP3996681A1 (fr) * 2019-07-12 2022-05-18 Kindeva Drug Delivery L.P. Formulation d'aérosol, cartouche et inhalateur contenant la formulation, et procédé d'utilisation
WO2021033081A1 (fr) * 2019-08-16 2021-02-25 Glenmark Pharmaceutical Limited Composition d'aérosol stable pour inhalation comprenant du glycopyrronium, du formotérol et des corticoïdes
CN112438966B (zh) * 2019-08-30 2022-08-26 四川普锐特药业有限公司 一种医用定量吸入气雾剂
MX2022004781A (es) 2019-12-02 2022-05-16 Chiesi Farm Spa Lata de acero inoxidable para inhaladores dosificadores presurizados.
US20210205223A1 (en) * 2020-01-04 2021-07-08 Cai Gu Huang Propellant-free formulation for inhalation
CA3163599A1 (fr) * 2020-01-28 2021-08-05 Enrico Zambelli Inhalateurs doseurs sous pression comprenant une formulation pharmaceutique tamponnee
AU2021223587A1 (en) * 2020-02-20 2022-09-29 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
CA3186956A1 (fr) 2020-07-31 2022-02-03 Chemo Research , S.L. Polytherapie destinee a une administration par inhalation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
SK286694B6 (sk) * 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
GB0315791D0 (en) * 2003-07-07 2003-08-13 3M Innovative Properties Co Two component molded valve stems
RU2438660C2 (ru) * 2004-02-06 2012-01-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
EP1595531A1 (fr) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression
EA200602112A1 (ru) * 2004-05-13 2007-04-27 Кьези Фармачеутичи С. П. А. Изделие для медицинского аэрозоля
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2201934A1 (fr) * 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Produits de formule d'aérosol de tiotropium avec stabilité chimique améliorée
WO2010144628A2 (fr) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Traitement d'une maladie pulmonaire obstructive chronique par administration de bêta 2 agoniste nébulisé ou d'une combinaison de bêta 2 agoniste nébulisé et d'anticholinergique
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
BR112012015335B1 (pt) 2009-12-23 2021-05-18 Chiesi Farmaceutici S.P.A. formulação de aerossol para doença pulmonar obstrutiva crõnica
SG181870A1 (en) * 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
PE20160853A1 (es) 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
MX2013013440A (es) * 2011-05-17 2014-06-05 Pearl Therapeutics Inc Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.
PL3089735T3 (pl) * 2013-12-30 2018-12-31 Chiesi Farmaceutici S.P.A. Trwała ciśnieniowa kompozycja roztworu aerozolowego kombinacji bromku glikopironium i formoterolu
WO2015101575A1 (fr) * 2013-12-30 2015-07-09 Chiesi Farmaceutici S.P.A. Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol

Also Published As

Publication number Publication date
UA117846C2 (uk) 2018-10-10
PT3096737T (pt) 2018-04-27
US20170095444A1 (en) 2017-04-06
AR098983A1 (es) 2016-06-22
CL2016001652A1 (es) 2017-08-25
JP6826145B2 (ja) 2021-02-03
CN105848642A (zh) 2016-08-10
JP6534397B2 (ja) 2019-06-26
ES2666905T3 (es) 2018-05-08
HUE039359T2 (hu) 2018-12-28
JP2019112458A (ja) 2019-07-11
WO2015101575A1 (fr) 2015-07-09
PL3096737T3 (pl) 2018-08-31
EA201691127A1 (ru) 2016-12-30
PH12016501269B1 (en) 2016-08-15
KR101865131B1 (ko) 2018-06-08
EP3096737A1 (fr) 2016-11-30
US20160303044A1 (en) 2016-10-20
JP2017507168A (ja) 2017-03-16
NZ721640A (en) 2021-02-26
PH12016501269A1 (en) 2016-08-15
KR20160104042A (ko) 2016-09-02
NO3096737T3 (fr) 2018-09-01
BR112016014586A2 (pt) 2017-08-08
MY176191A (en) 2020-07-24
CA2935302C (fr) 2022-06-21
MX368834B (es) 2019-10-18
EA033228B1 (ru) 2019-09-30
SA516371428B1 (ar) 2018-09-30
HRP20180944T1 (hr) 2018-08-10
MX2016008591A (es) 2016-09-26
CN113143894A (zh) 2021-07-23
RS57269B1 (sr) 2018-08-31
IL246502A0 (en) 2016-08-31
SG11201605309UA (en) 2016-07-28
PE20161132A1 (es) 2016-11-02
US20150182459A1 (en) 2015-07-02
DK3096737T3 (en) 2018-06-25
TN2016000262A1 (en) 2017-10-06
SI3096737T1 (en) 2018-07-31
LT3096737T (lt) 2018-06-11
AU2014375300B2 (en) 2019-10-24
CY1120205T1 (el) 2018-12-12
GEP20186870B (en) 2018-06-25
IL246502B (en) 2020-05-31
ES2666905T4 (es) 2018-06-07
EP3096737B1 (fr) 2018-04-04
US10596149B2 (en) 2020-03-24
AU2014375300A1 (en) 2016-07-14
TR201809356T4 (tr) 2018-07-23
ME03076B (fr) 2019-01-20
CA2935302A1 (fr) 2015-07-09
US10617669B2 (en) 2020-04-14

Similar Documents

Publication Publication Date Title
MA39154A1 (fr) Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol
MA39155A1 (fr) Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol
AR081540A1 (es) Proceso para proveer particulas con cargas electroestaticas reducidas
PE20160155A1 (es) Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
MA33823B1 (fr) Polythérapie pour bronchopneumopathie chronique obstructive (copd)
NZ600789A (en) Aerosol formulation for copd
UA111343C2 (uk) Фармацевтична композиція, що містить мометазону фуроат та азеластину гідрохлорид, для назального введення
JP2010132695A5 (fr)
JP2008500987A5 (fr)
BR112022014228A2 (pt) Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada
JP2019528316A5 (fr)
ES2247959T1 (es) Formulacion medica en aerosol estabilizada en agua.
CA3193038A1 (fr) Formulation pharmaceutique pour inhalateur doseur pressurise
JP2014527056A5 (fr)
JP2011500731A5 (fr)
TH171993A (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
TH171992A (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
PL432374A1 (pl) Nowy inhalacyjny system terapeutyczny dostarczający zredukowaną ilość propionianu flutikazonu i salmeterolu o zwiększonej skuteczności i profilu bezpieczeństwa
RU2021104054A (ru) Ингалятор отмеренных доз с распылением сжатым воздухом, содержащий забуференный фармацевтический состав
WO2023227781A1 (fr) Formulation pharmaceutique pour aérosol-doseur sous pression
WO2023227782A1 (fr) Formulation pharmaceutique pour aérosol-doseur pressurisé
Cuomo et al. D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Effect Of Organic Cation Transport Inhibition On The Pharmacokinetics Of Glycopyrronium Bromide In Fixed Combination With Beclomethasone Dipropionate And Formoterol Fumarate
TH171993B (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
TH171992B (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล